(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a-ethyl-6-(2-hydroxy-3,3-dimethylbutan-2-yl)-7-methoxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a-ethyl-6-(2-hydroxy-3,3-dimethylbutan-2-yl)-7-methoxy-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol
• 化学式: C₂₉H₄₃NO₄
• 分子量: 469.7
• InChiKey: SFRYILDDMBQAQS-RFNLUXJXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• TWO-COMPONENT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PAIN
  申请人：Applied Pharmacy Services, Inc.

  公开号：US20140080818A1

  公开（公告）日：2014-03-20

  The present invention is directed to a pharmaceutical composition that includes a combination of about 2-5 milligrams of a non-steroidal anti-inflammatory drug and from about 2-30 milligrams of an opioid analgesic in a single pharmaceutical dosage unit that can provide effective chronic pain management with the added benefit of reduced side effects such as withdrawal and gastrointestinal disorders. The non-steroidal anti-inflammatory drug may be piroxicam and the opioid analgesic may be buprenorphine. The present invention also provides for a method of managing pain in a patient that includes administering the pharmaceutical composition previously described. The pharmaceutical composition previously described may be administered in a single or multiple dosage regimens.